Publications by authors named "Tetsuhiro Soeda"

Claim this Profile
I
Infrared thermography for detecting compensatory load in people with haemophilia: a cross-sectional study.
Yuya Mawarikado, Asuka Sakata, Midori Shima, Chihiro Hosoda, Naoki Matsumoto, Tetsuhiro Soeda

Thromb J· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of VEGFA and ANGPT2 Antibodies on the Activation of Microglia in the Early Stages of Streptozotocin-Induced Pathogenesis of Diabetic Retinopathy.
Toshiro Iwagawa, Yuta Inokuchi, Kosuke Saita, Tetsuhiro Soeda, Ayumi Usui-Ouchi

Genes Cells· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Dual Inhibition of VEGF-A and Angpt-2 on Angiogenesis and Lymphangiogenesis in an Alkali-Induced Corneal Injury Model.
Hiroshi Kuribayashi, Toshiro Iwagawa, Souta Kadohara, Hirokazu Ohashi, Chihiro Kawaji, Tetsuhiro Soeda

Genes Cells· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extravascular coagulation regulates haemostasis independently of activated platelet surfaces in an in vivo mouse model.
Asuka Sakata, Kohei Tatsumi, Naoki Matsumoto, Nigel Mackman, Suguru Harada, Tetsuhiro Soeda

Commun Biol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Î
β-hydroxybutyrate suppresses pathological changes of blood-induced arthropathy in rats.
Ryohei Kawasaki, Asuka Sakata, Kohei Tatsumi, Seiji Mitani, Maiko Takeda, Tetsuhiro Soeda

Sci Rep· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The protective effect of anti-VEGF-A/Ang-2 bispecific antibody on retinal vein occlusion model mice.
Aika Kuriyama, Shinsuke Nakamura, Yuta Inokuchi, Hiroto Abe, Hiroto Yasuda, Tetsuhiro Soeda

Eur J Pharmacol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced plasma factor X is associated with a lack of response to recombinant activated factor VII in patients with hemophilia A and inhibitor, but does not impair emicizumab-driven hemostasis in vitro.
Koji Yada, Natsume Fujitate, Kenichi Ogiwara, Tetsuhiro Soeda, Takehisa Kitazawa

Thromb Res· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state.
Yuri Teranishi-Ikawa, Tetsuhiro Soeda, Hikaru Koga, Kazuki Yamaguchi, Kazuki Kato

J Thromb Haemost· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emicizumab-mediated hemostatic function assessed by thrombin generation assay in an in vitro model of factor VIII-depleted thrombophilia plasma.
Koji Yada, Kenichi Ogiwara, Naruto Shimonishi, Yuto Nakajima, Tetsuhiro Soeda

Int J Hematol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The in vitro effect of anticoagulant agents on coagulation and fibrinolysis in the presence of emicizumab in the plasmas from patients with haemophilia A.
Tomoko Onishi, Suguru Harada, Hanako Shimo, Yoshihito Tashiro, Tetsuhiro Soeda

Haemophilia· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Coagulant potentials of emicizumab in the plasmas from infant and toddler patients with hemophilia A.
Masahiro Takeyama, Naoki Matsumoto, Hiroto Abe, Suguru Harada, Kenichi Ogiwara, Tetsuhiro Soeda

Pediatr Blood Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of Anti-Emicizumab Antibodies Using Repository Samples Obtained in Clinical Studies of Emicizumab Conducted in Japan.
Naoki Matsumoto, Hiroto Abe, Ryohei Kawasaki, Yoshihito Tashiro, Mariko Noguchi-Sasaki, Tetsuhiro Soeda

TH Open· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of infrared thermography for non-invasive detection of bleeding and musculoskeletal abnormalities in patients with hemophilia: an observational study.
Ryohei Kawasaki, Asuka Sakata, Chihiro Hosoda, Suguru Harada, Tetsuhiro Soeda

Thromb J· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-idiotype monoclonal antibodies against emicizumab enable accurate procoagulant and anticoagulant assays, irrespective of the test base, in the presence of emicizumab.
Kenichi Ogiwara, Shoko Furukawa, Sho Shinohara, Yuka Tabuchi, Nobuo Arai, Tetsuhiro Soeda

Haemophilia· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A.
Makoto Kaneda, Ryohei Kawasaki, Naoki Matsumoto, Hiroto Abe, Yoshihito Tashiro, Tetsuhiro Soeda

J Thromb Haemost· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
Kenichi Ogiwara, Keiji Nogami, Naoki Matsumoto, Mariko Noguchi-Sasaki, Michinori Hirata, Tetsuhiro Soeda

Int J Hematol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emicizumab improves the stability and structure of fibrin clot derived from factor VIII-deficient plasma, similar to the addition of factor VIII.
Naruto Shimonishi, Keiji Nogami, Kenichi Ogiwara, Tomoko Matsumoto, Fumie Nakazawa, Tetsuhiro Soeda

Haemophilia· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The factor VIII heavy chain improves emicizumab-tenase assembly to enhance the factor VIII-mimicking cofactor activity.
Hiroaki Minami, Keiji Nogami, Tetsuhiro Soeda, Takehisa Kitazawa, Kunihiro Hattori

Thromb Res· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emicizumab, A Bispecific Antibody to Factors IX/IXa and X/Xa, Does Not Interfere with Antithrombin or TFPI Activity In Vitro.
Mariko Noguchi-Sasaki, Tetsuhiro Soeda, Atsunori Ueyama, Atsushi Muto, Michinori Hirata

TH Open· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens.
Takehisa Kitazawa, Keiko Esaki, Tatsuhiko Tachibana, Shinya Ishii, Tetsuhiro Soeda

Thromb Haemost· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity.
Zenjiro Sampei, Tomoyuki Igawa, Tetsuhiro Soeda, Miho Funaki, Kazutaka Yoshihashi

MAbs· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A.
Atsushi Muto, Kazutaka Yoshihashi, Minako Takeda, Takehisa Kitazawa, Tetsuhiro Soeda

Blood· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity.
Zenjiro Sampei, Tomoyuki Igawa, Tetsuhiro Soeda, Yukiko Okuyama-Nishida, Chifumi Moriyama

PLoS One· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.
Takehisa Kitazawa, Tomoyuki Igawa, Zenjiro Sampei, Atsushi Muto, Tetsuo Kojima, Tetsuhiro Soeda

Nat Med· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterisation of an antibody specific for coagulation factor VIII that enhances factor VIII activity.
Masahiro Takeyama, Keiji Nogami, Tomoko Matsumoto, Tetsuhiro Soeda, Tsukasa Suzuki

Thromb Haemost· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis